Select Page
  1. Home
  2.  » 
  3. Catalent News
  4.  » Biohaven announces Expanded Access Program for Patients with ALS

Catalent’s partner, Biohaven, announces it has Initiated Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Catalent’s partner, Biohaven, announces it has Initiated Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Learn more